The Exchange has sought clarification from Lotus Eye Hospital and Institute Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
LOTUSEYE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The National Stock Exchange has asked Lotus Eye Hospital and Institute to clarify why segment-wise details were not submitted along with its financial results for the quarter ended 31 March 2025, under Regulation 33 of SEBI's Listing Obligations and Disclosure Requirements. This is a routine compliance query raised because the company's quarterly results filing was incomplete on the segment reporting front. The company has not yet responded to the exchange. Investors should wait for the company's clarification, which should clarify any segment-level revenue and profit break-up typically expected from healthcare chains.
This is a procedural compliance matter and not a penalty or enforcement action. It is unlikely to materially affect the stock price, but the company's response on segment performance could provide additional insight into how different business lines are contributing to overall results.